SCHEMBL25367016

SCHEMBL25367016

Nc1nccc(Oc2ccc(NC(=O)c3nccn(-c4ccc(F)cc4)c3=O)cc2F)c1C#CC(=O)N1CCN(C(=O)O)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 2/20 0.60
▸ RIPK1 Q13546 2/20 0.60
▸ RIPK3 Q9Y572 2/20 0.60
▸ MET P08581 17/20 0.59
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ AXL P30530 5/20 0.51
▸ TYRO3 Q06418 4/20 0.51
▸ MST1R Q04912 2/20 0.51
▸ MERTK Q12866 3/20 0.51
▸ PLK4 O00444 1/20 0.50
▸ ABL1 P00519 1/20 0.50
▸ NTRK1 P04629 1/20 0.50
▸ LCK P06239 1/20 0.50
▸ RET P07949 1/20 0.50
▸ KIT P10721 1/20 0.50
▸ PDGFRA P16234 1/20 0.50
▸ PRKACA P17612 1/20 0.50
▸ KDR P35968 1/20 0.50
▸ FLT3 P36888 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25366637 0.93 RIPK1 (0.60) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL25366715 0.92 RIPK1 (0.59) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL25365777 0.91 RIPK2 (0.58) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL25366374 0.90 RIPK2 (0.58) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL25364760 0.90 RIPK3 (0.76) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL25366910 0.82 RIPK3 (0.75) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL26317345 0.82 RIPK3 (0.75) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL26317365 0.82 RIPK3 (0.74) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL30530993 0.81 RIPK3 (0.73) RIPK2RIPK1RIPK3METCYP3A4
SCHEMBL26034229 0.81 RIPK3 (0.73) RIPK2RIPK1RIPK3METCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023156864-A1 PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-08-24 — — WO disclosed
US-20230257364-A1 PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF CMG PHARMACEUTICAL CO., LTD. (KR) 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257364-A1 PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF MERTK, MET, AXL RIPK2 1519/4885RIPK1 1682/4885RIPK3 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback